Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

Please sign in to follow a disease.

← Back to home

Lisa Satter

Clinical trials sponsored by Lisa Satter, explained in plain language.

Not yet recruiting 1

New hope for rare immune disorders: upadacitinib trial launches

Disease control Not yet recruiting

This study tests the drug upadacitinib (Rinvoq) in 30 people with rare genetic disorders that overactivate the JAK-STAT immune pathway. The trial has four phases over 12 months, including an open-label phase to find the best dose and a randomized withdrawal phase to compare the d…

Phase 1/2 • Sponsor: Lisa Satter • Aim: Disease control

Last updated Sep 10, 2026 00:00 UTC